Combining Immunoreactive Trypsinogen and Pancreatitis-Associated Protein Assays, a Method of Newborn Screening for Cystic Fibrosis that Avoids DNA Analysis
Abnormalities of circulating immunoreactive pancreatic anionic trypsinogen in cystic fibrosis: An assay artifact due to cross-reacting serum antibodies
Pancreatic function and extended mutation analysis in ΔF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels
Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen
Evaluation of the Quantase™ neonatal immunoreactive trypsinogen (IRT) screening assay for cystic fibrosis
Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels
